Federal regulators have sent Bausch & Lomb a warning letter over contamination concerns at its Tampa, Florida, manufacturing site. The facility produces both prescription and over-the-counter eye medications, according to the Fierce Pharma report on the letter.
The letter marks a formal escalation following the agency's concerns about the plant's conditions. Because this article relies on a single source, there are no conflicting reports to weigh, and the specific contaminants or the timing of the FDA's inspection have not been disclosed.
The warning letter is a regulatory step that can lead to further enforcement if the company fails to address the issues. Bausch & Lomb has not yet publicly responded, per the report.